Market Place
Sourcing Support
Elevation lifts HER3 ADC toward clinic with $368M Synaffix deal
12 Dec 2024 //
FIERCE BIOTECH
Elevation Oncology Reports Q3 2024 Results & Business Highlights
06 Nov 2024 //
PR NEWSWIRE
Elevation Oncology Gets FDA Fast Track For EO-3021 In Cancer
23 Sep 2024 //
PR NEWSWIRE
Elevation Oncology to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
PR NEWSWIRE
Elevation Oncology Announces Promising Data For EO-3021 Trial
06 Aug 2024 //
PR NEWSWIRE
Elevation Oncology Reports Q2 2024 Results And Achievements
06 Aug 2024 //
PR NEWSWIRE
Elevation Oncology Announces Planned Combination Strategy for EO-3021
27 Jun 2024 //
PR NEWSWIRE
Elevation Oncology Presents Preclinical Data for HER3-ADC Program at AACR
08 Apr 2024 //
PR NEWSWIRE
Elevation to Present Preclinical Proof-of-Concept Data for HER3-ADC Program
05 Mar 2024 //
PR NEWSWIRE
Elevation Oncology to Participate in Upcoming Investor Conferences
28 Feb 2024 //
PR NEWSWIRE
Elevation Oncology Announces Appointment of Darcy Mootz to Board of Directors
22 Jan 2024 //
PR NEWSWIRE
Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones
05 Jan 2024 //
PR NEWSWIRE
Elevation to Present at the Piper Sandler 35th Annual Healthcare Conference
22 Nov 2023 //
PR NEWSWIRE
Elevation Oncology to Present at the H.C. Wainwright 25th Investment Conference
05 Sep 2023 //
PR NEWSWIRE
Elevation Announces First Patient Dosed in the Phase 1 Trial Evaluating EO-3021
16 Aug 2023 //
PR NEWSWIRE
Elevation Oncology Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
PR NEWSWIRE
Elevation Appoints Joseph Ferra as CEO and Promotes Tammy Furlong to CFO
13 Jul 2023 //
PR NEWSWIRE
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 Clinical Data
03 Jun 2023 //
PR NEWSWIRE
Elevation Oncology Reports First Quarter 2023 Financial Results
15 May 2023 //
PRESS RELEASE
Elevation Oncology Reports 1Q 2023 FYR & Highlights Recent Business
15 May 2023 //
PR NEWSWIRE
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021)
26 Apr 2023 //
PR NEWSWIRE
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept & Highlights
17 Apr 2023 //
PR NEWSWIRE
Elevation Oncology to Present at the AACR Annual Meeting 2023
14 Mar 2023 //
PR NEWSWIRE
Elevation Oncology to Present at the SVB Securities Global Biopharma Conference
08 Feb 2023 //
PR NEWSWIRE
Elevation Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
09 Jan 2023 //
PR NEWSWIRE
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources
06 Jan 2023 //
PR NEWSWIRE
Century, Elevation to cut assets, staff; Nabriva winds down
06 Jan 2023 //
FIERCE BIOTECH
Elevation Oncology to Participate at the JMP Securities Hematology
30 Nov 2022 //
PRNEWSWIRE
Elevation Oncology Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
PRNEWSWIRE
Elevation Oncology sets out for clinic climb in $27M ADC deal
28 Jul 2022 //
FIERCEBIOTECH
Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021
28 Jul 2022 //
PRNEWSWIRE
Elevation Oncology to Participate at Cowen`s 3rd Oncology Innovation Summit
01 Jun 2022 //
PRNEWSWIRE
Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data at ASCO
26 May 2022 //
PRNEWSWIRE
Elevation Oncology Reports First Quarter 2022 Financial Results
05 May 2022 //
PRNEWSWIRE
Elevation Oncology Shows Initial Data from PII CRESTONE Study of Seribantumab
27 Apr 2022 //
PRNEWSWIRE
Elevation Oncology Appoints David Dornan, Ph.D., as Chief Scientific Officer
14 Mar 2022 //
PRNEWSWIRE
Elevation Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
03 Mar 2022 //
PRNEWSWIRE
Elevation Oncology Highlights 2021 Achievements, Outlines 2022 Milestones
10 Jan 2022 //
PRNEWSWIRE
Elevation Oncology`s Seribantumab Included as Part of a Case Series Presentation
14 Oct 2021 //
PRNEWSWIRE
Elevation Oncology to Present at H.C. Wainwright Investment Conference
07 Sep 2021 //
PRNEWSWIRE
Elevation Oncology Reports Second Quarter 2021 Financial Results
12 Aug 2021 //
PRNEWSWIRE
Merrimack Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
BUSINESSWIRE
Oncology biotech Elevation Oncology sets terms for $100 million IPO
21 Jun 2021 //
RENAISSANCECAPITAL
Elevation files for $100M IPO to fund tumor-agnostic candidate
08 Jun 2021 //
FIERCEBIOTECH
Elevation files for $100M IPO to fund tumor-agnostic candidate
07 Jun 2021 //
FIERCEBIOTECH
Elevation Announces the Presentation of New Preclinical Data in Pancreatic
09 Apr 2021 //
PRNEWSWIRE
Elevation Oncology Announces Clinical Cancer Research Publication
06 Apr 2021 //
PRNEWSWIRE
Elevation Oncology and NeoGenomics Announce Collaboration
16 Mar 2021 //
PRNEWSWIRE
Elevation Raises $65 Million to Advance Treatment for Genomically Defined Tumors
20 Nov 2020 //
GLOBAL GENES
Elevation Oncology Announces the Presentation of Preclinical Data
26 Oct 2020 //
PRNEWSWIRE
Elevation Oncology Announces the Presentation of Preclinical Data
26 Oct 2020 //
PRNEWSWIRE
Elevation Oncology and US Oncology Research Announce Collaboration
30 Sep 2020 //
PRNEWSWIRE
